MARKET

VXRT

VXRT

VAXART
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.37
-0.63
-7.88%
Pre Market: 7.13 -0.24 -3.26% 08:58 07/06 EDT
OPEN
8.05
PREV CLOSE
8.00
HIGH
8.15
LOW
7.10
VOLUME
331.26K
TURNOVER
--
52 WEEK HIGH
14.30
52 WEEK LOW
0.2543
MARKET CAP
546.74M
P/E (TTM)
-8.5232
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VXRT stock price target is 6.50 with a high estimate of 7.00 and a low estimate of 6.00.

EPS

VXRT News

More
Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron
MotleyFool.com · 1d ago
Why Emergent BioSolutions Stock Soared 47% in the First Half of 2020
MotleyFool.com · 2d ago
These 3 Things Could Send Novavax's Stock Soaring to New Heights
MotleyFool.com · 3d ago
Jim Cramer deciphers the speculative and blue-chip stocks driving the market
"The whole market's being upended by the pandemic and the lines they are shifting," the "Mad Money" host said.
CNBC.com · 4d ago
Cramer Shares His Thoughts On Sirius XM, Nokia And More
Benzinga · 4d ago
Cramer Shares His Thoughts On Sirius XM, Nokia And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said it's not setting up as being a great time for Berkshire Hathaway (NYSE: BRK-A).
Benzinga · 4d ago
Could Investing in Vaxart Make You a Millionaire?
Motley Fool · 4d ago
Smaller cap COVID-19 vaccine players under pressure on Pfizer data
Seeking Alpha - Article · 4d ago

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About VXRT

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
More

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.